🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Generation of allogenic CAR invariant natural killer T (CAR-NKT) cells from HSC. Anti-CD33 CAR-NKT cells exhibit strong BM homing and effectively target AML and MDS blasts. TCR-CD1d and NK receptors help in the elimination of leukemic stem cells. nature.com/articles/s4146…

Clonal expansion of CD8+ T cells is an immunological driver of bispecific T cell engagers (TCE) Naive T cells require additional MHC class I signal and differentiate upon TCE activation Exhausted CD8+ clones predicts response failure in multiple myeloma cell.com/cancer-cell/fu…

Hace 20 años que creamos nuestra Fundación. Hoy nos unimos a la UAM para seguir apoyando la investigación, los tratamientos y la formación en Oncología Pediátrica Siempre agradecido de como me acogieron en el HNJS y los excelentes médicos que conocí y con los que sigo colaborando

Methyltransferases EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models Treated tumors showed upregulation of genes related to adhesion, B cell activation, and inflammatory responses, and increased avidity to CAR-T cell.com/cancer-cell/ab…

La inversión en ciencia es rentable. Barcelona: un ejemplo a seguir 👇

T cell receptor precision editing of regulatory T cells for celiac disease. Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs. e Tregs hold therapeutic potential for restoring gluten tolerance in their mice model. science.org/doi/epdf/10.11…

Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies. Minireview: frontiersin.org/journals/immun…

In the pilot phase, no clinical responses were observed in 18 patients unselected TILs. However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%). Pembrolizumab was added, and 8 objective responses were seen in 34 patients (23.5%)

Coming soon, see you in Madrid (Majadahonda) !!!

🔬 Workshop on Adoptive Cell Therapies! 🔬 Open scientific workshop on May 28, 2025, hosted at the Majadahonda Campus of ISCIII (Madrid-Spain). 🎟️ Free access — but registration is required via email: [email protected]

Join us May 28 at ISCIII Majadahonda (Madrid, Spain) 🏨for the Workshop on Adoptive Cell Therapies — dive into the latest on CAR-T and adoptive therapies 💉🧬 Free registration via email: [email protected] Don't miss out!"

El Instituto de Salud Carlos III (ISCIII) acoge un encuentro internacional sobre terapias avanzadas. Organizado por el #IIER, con el apoyo de la Red Española de terapias Avanzadas (Red TERAV+ ISCIII). isciii.es/documents/d/gu… Javier García Castro Luis Mariñas Pardo

Hoy arranca la jornada principal del Encuentro Internacional sobre Terapias Avanzadas, que celebramos en nuestro campus de Majadahonda. TERAV Más de 1️⃣0️⃣0️⃣ expertos se reúnen para compartir avances en terapias y salas blancas al servicio de los pacientes.